almost
decad
sinc
emerg
sever
acut
respiratori
syndrom
coronaviru
anoth
novel
coronaviru
emerg
human
middl
east
respiratori
syndrom
coronaviru
isol
patient
experienc
sever
pneumonia
kingdom
saudi
arabia
ksa
infect
human
mortal
rate
mainli
countri
arabian
dromedari
camel
strongli
believ
intermedi
host
import
sourc
infect
although
exact
transmiss
mechan
still
transmiss
document
although
requir
close
lengthi
contact
part
case
mild
asymptomat
fatal
case
result
comorbid
diabet
mellitu
type
preval
arabian
asymptomat
case
estim
time
higher
report
togeth
mild
case
may
serv
spread
viru
camel
human
primari
case
contact
infect
patient
like
contact
camel
directli
howev
camel
believ
intermedi
specul
bat
could
primari
dromedari
camel
seroposit
sampl
date
back
earli
african
arabian
peninsula
spanish
canari
australian
dromedari
camel
bactrian
sever
group
report
viral
shed
infect
nevertheless
despit
impress
quick
elucid
mani
issu
gap
understand
emerg
viru
precis
rout
transmiss
infect
risk
factor
contract
viru
protect
level
neutral
antibodi
nab
importantli
date
specif
antivir
vaccin
treatment
prevent
infect
articl
review
ongo
effort
vaccin
develop
shed
light
challeng
hinder
progress
speed
develop
vaccin
tropism
human
camel
determin
bind
spike
glycoprotein
dipeptidyl
peptidas
surfac
mammalian
cell
respiratori
epitheli
cell
howev
viru
infect
small
experiment
anim
mice
ferret
rat
hamster
mainli
differ
anim
therefor
pose
challeng
develop
vaccin
delay
scientif
investig
viru
infect
pathogen
transmiss
rabbit
model
report
support
small
anim
model
requir
acceler
research
therefor
suscept
mous
model
develop
differ
method
first
model
develop
transduc
mice
adenovir
vector
encod
human
deliv
intranas
enabl
mous
cell
respiratori
tract
express
allow
viral
entri
model
easi
use
readili
appli
broad
rang
mous
strain
especi
laboratori
transgen
anim
facil
avail
model
develop
gener
transgen
mice
either
express
human
replac
murin
human
develop
help
evalu
vaccin
monoclon
therapi
small
laboratori
anim
although
one
main
clinic
manifest
mer
human
patient
kidney
failur
support
biochem
test
viru
tropism
kidney
cell
mer
mous
model
support
show
viru
viral
rna
isol
kidney
larg
anim
nonhuman
primat
nhp
support
mer
common
marmoset
show
moder
sever
infect
compar
mild
infect
rhesu
macaqu
review
van
doremalen
dromedari
camel
strongli
believ
intermedi
host
one
sourc
infect
although
mechan
transmit
viru
human
subject
yet
investig
determin
replic
upper
respiratori
tract
camel
unlik
human
infect
affect
mainli
lung
lower
respiratori
tract
result
mild
clinic
manifest
rhinorrhea
experiment
camel
model
infecti
virus
detect
nasal
oropharyng
swab
tissu
day
postinfect
wherea
viral
rna
persist
sampl
develop
studi
anim
model
conduct
less
year
acceler
understand
respons
vaccin
alreadi
test
mous
nhp
camel
model
discuss
section
figur
tabl
although
seem
long
way
go
establish
robust
anim
model
assess
immunogen
efficaci
vaccin
candid
soon
identif
sever
group
develop
vaccin
preclin
test
recombin
domain
rrbd
residu
spike
protein
express
test
mice
induc
immunoglobulin
g
igg
antibodi
test
variou
adjuv
alum
cpg
p
c
ifa
howev
rbd
alum
alum
cpg
abl
induc
vaccin
taken
test
rhesu
macaqu
differ
dosag
homolog
vaccin
regimen
interv
dose
induc
strong
antibodi
week
vaccin
similar
nab
titer
significantli
higher
monkey
compar
control
anim
dose
vaccin
reduc
interstiti
infiltr
gross
patholog
lung
anim
challeng
tabl
vaccin
reduc
viral
rna
load
lung
trachea
tissu
throat
nasal
rectal
swab
sampl
howev
reduct
viral
load
statist
signific
throat
swab
vaccin
anim
summar
tabl
dose
also
reduc
infecti
viru
titer
lung
trachea
around
moreov
specul
nab
underli
mechan
partial
protect
cellular
respons
test
secret
peripher
blood
monocyt
detect
anim
immun
highest
dose
vaccin
seri
studi
also
conduct
first
defin
minimum
sequenc
rbd
focu
immun
studi
conclud
residu
protein
minimum
rbd
region
abl
induc
highest
nab
level
mice
test
microneutr
assay
differ
adjuv
test
rrbd
vaccin
freund
adjuv
alum
mpla
induc
highest
igg
antibodi
subtyp
neutral
induc
higher
immun
respons
freund
adjuv
wherea
alum
mpla
induc
immun
respons
rrbd
vaccin
induc
respons
similar
without
subunit
vaccin
appeal
found
inactiv
whole
use
vaccin
result
enhanc
lung
immunopatholog
vaccin
anim
challeng
attribut
presenc
antibodi
rather
therefor
use
whole
antigen
vaccin
could
safe
use
minimum
rbd
fact
studi
report
nab
titer
direct
part
outsid
rbd
linear
synthes
peptid
correspond
residu
protein
subunit
away
rbd
induc
nab
titer
mice
titer
lower
use
rrbd
synthes
peptid
base
immunoepitop
subunit
spike
protein
rbd
region
induc
bind
support
use
antigen
vaccin
develop
nanoparticl
trimer
protein
produc
vaccin
baculoviru
express
system
use
immun
balbc
mice
alum
matrix
adjuv
latter
induc
significantli
higher
nab
level
higher
alum
moreov
differ
high
low
dose
prime
boost
separ
studi
antigen
test
mice
differ
form
without
transmembran
domain
subunit
form
test
homolog
regimen
mice
prime
boost
regimen
sequenti
dna
vaccin
ddd
prime
boost
regimen
sequenti
protein
vaccin
pp
heterolog
regimen
prime
boost
regimen
sequenti
dna
vaccin
follow
protein
vaccin
ddp
studi
conclud
dna
protein
induc
highest
nab
titer
ddp
pp
regimen
note
protein
vaccin
nab
titer
mice
distinct
isol
could
predict
rbd
sequenc
highli
conserv
isol
studi
also
show
vaccin
dna
import
achiev
maxim
neutral
activ
therefor
vaccin
base
full
antigen
test
rhesu
macaqu
use
ddd
pp
ddp
regimen
studi
use
alum
adjuv
vaccin
ddp
follow
tightli
pp
reduc
peak
proport
volum
pulmonari
consolid
measur
comput
tomographi
ct
anim
challeng
tabl
therefor
seem
regimen
involv
vaccin
superior
vaccin
drive
protect
anoth
encourag
studi
also
report
partial
protect
nhp
use
dna
vaccin
base
consensu
sequenc
vaccin
deliv
rhesu
macaqu
homolog
dna
vaccin
interv
induc
high
titer
nab
reduc
viral
rna
load
lung
tissu
vaccin
anim
compar
control
upon
challeng
tabl
radio
examin
histolog
gross
patholog
normal
vaccin
monkey
mild
infect
tabl
mice
vaccin
shown
induc
high
igg
level
neutral
pseudotyp
viral
particl
merspp
neutral
assay
merspp
base
sequenc
clinic
isol
well
consensu
gene
importantli
vaccin
first
undergo
camel
immun
two
vaccin
dromedari
camel
develop
antibodi
tabl
overal
vaccin
induc
high
titer
nab
mice
camel
monkey
advanc
human
clinic
trial
discuss
next
section
recombin
mva
encod
antigen
use
immun
balbc
mice
via
intramuscular
subcutan
rout
homolog
prime
boost
three
differ
dose
mva
induc
compar
nab
titer
intramuscular
group
wherea
subcutan
vaccin
lower
dose
induc
high
level
nab
especi
postprim
use
merspp
neutral
assay
compar
rout
intramuscular
rout
elicit
higher
nab
titer
trend
also
observ
cellular
immun
respons
measur
immunospot
assay
elispot
challeng
experi
immun
mice
first
transduc
render
suscept
infect
upon
challeng
intramuscular
rout
vaccin
drove
reduct
undetect
viral
rna
load
protect
less
evid
subcutan
vaccin
dromedari
camel
relev
anim
speci
vaccin
mva
given
intramuscular
intranas
simultan
anim
boost
week
later
manner
vaccin
postprim
vaccin
anim
develop
nab
boost
nab
level
high
vaccin
anim
three
week
boost
vaccin
camel
challeng
via
intranas
rout
tabl
promis
result
vaccin
camel
show
rhinorrhea
compar
control
group
signific
reduct
viral
genom
complet
absent
infecti
virus
observ
nasal
swab
low
viral
rna
load
detect
infecti
virus
isol
rectal
swab
serum
sampl
vaccin
camel
clear
viru
viral
rna
wide
rang
examin
organ
vaccin
camel
low
undetect
rna
level
infecti
virus
compar
control
anim
look
control
group
alon
infecti
obtain
nasal
tracheal
tissu
partial
protect
vaccin
shown
reduc
viral
shed
also
confirm
immunohistochemistri
situ
vaccin
head
phase
clinic
trial
recombin
measl
viru
also
develop
vector
vaccin
use
antigen
either
antigen
express
infect
cell
surfac
solubl
version
antigen
secret
infect
cell
lack
transmembran
cytoplasm
test
immunocompromis
mice
vaccin
twice
month
interv
vaccin
induc
nab
cellular
immun
respons
elispot
mice
transduc
subsequ
challeng
vaccin
mice
show
reduct
viral
rna
load
infecti
viru
titer
lung
tissu
partial
protect
also
confirm
histopatholog
immunohistochemistri
lung
experi
solubl
similar
nonsolubl
vaccin
vaccin
base
adenovir
vector
develop
differ
group
use
human
adenoviru
type
first
group
use
vector
encod
either
antigen
antigen
immun
balbc
mice
prime
boost
vaccin
intramuscular
rout
prime
intranas
rout
boost
level
similar
antigen
increas
time
boost
peak
level
plateau
week
postboost
similarli
nab
level
doubl
boost
plateau
second
group
use
vector
deriv
viru
infect
human
natur
via
gastrointestin
rout
make
suitabl
vector
induc
mucos
immun
allow
oral
immun
therefor
viral
vector
deliv
mer
antigen
test
comparison
balbc
mice
mice
vaccin
via
intramuscular
intragastr
rout
respect
intramuscular
vaccin
induc
higher
titer
total
igg
antibodi
intragastr
rout
either
vector
use
merspp
neutral
assay
nab
titer
follow
trend
intramuscular
vaccin
induc
highest
nab
titer
although
hypothes
induc
mucos
immun
intramuscular
rout
show
secret
cell
lung
well
human
adenovir
vector
safeti
issu
highli
preval
preexist
immun
human
popul
elimin
adenovir
vector
hinder
immun
respons
encod
vaccin
antigen
may
affect
hiv
vaccin
efficaci
step
clinic
trial
despit
encourag
preclin
prompt
scientist
search
adenovirus
less
natur
exposur
human
simian
adenoviru
type
safe
immunogen
evalu
chimpanze
adenoviru
isol
develop
vaccin
call
chimpanze
adenoviru
develop
oxford
univers
vector
version
evalu
dromedari
camel
saudi
arabia
vaccin
rift
valley
fever
requir
singl
dose
infecti
unit
given
intramuscular
elicit
high
titer
nab
camel
also
test
influenza
vaccin
camel
human
show
excel
safeti
immunogen
therefor
vaccin
base
develop
prof
sarah
gilbert
group
univers
oxford
induc
high
antibodi
titer
balbc
mice
work
prepar
public
vaccin
also
test
dromedari
camel
human
unit
kingdom
saudi
arabia
nearli
vaccin
develop
base
protein
version
induc
nab
howev
elicit
cellular
immun
achiev
vaccin
encod
intern
antigen
nucleocapsid
protein
n
immunoepitop
n
protein
vrp
encod
epitop
nucleocapsid
protein
develop
test
balbc
mous
model
induc
airway
cell
abl
activ
dendrit
cell
migrat
lymph
node
turn
stimul
cytotox
cell
result
complet
protect
vaccin
mice
immun
prime
boost
research
develop
vaccin
base
n
epitop
analogu
similar
result
obtain
deplet
airway
cell
inhibit
airway
significantli
decreas
protect
addit
fact
n
epitop
weak
epitop
support
role
import
airway
cell
control
infect
well
vaccin
develop
mice
immun
show
sever
human
cov
includ
moder
level
protect
upon
challeng
studi
clearli
support
cellular
immun
role
develop
vaccin
pave
way
toward
univers
encount
exist
potenti
emerg
human
cov
studi
vaccin
develop
pathogen
show
rang
technic
variabl
may
allow
compar
result
variou
vaccin
studi
show
rang
possibl
way
appli
vaccin
instanc
challeng
experi
immun
nhp
show
partial
protect
despit
differ
vaccin
construct
platform
dose
rout
immun
dose
challeng
viru
differ
isol
also
use
challeng
summar
tabl
moreov
variou
gene
sequenc
differ
strain
use
construct
vaccin
discuss
articl
mostli
strain
addit
assess
nab
titer
perform
microneutr
assay
base
infecti
viru
differ
isol
use
mostli
report
viral
nab
titer
test
vnt
howev
experiment
set
use
assay
sera
differ
sourc
eg
mice
nhp
camel
human
differ
vaccin
platform
dna
protein
viral
vector
compar
report
vnt
exampl
vaccin
given
twice
mice
induc
lower
vnt
vaccin
given
twice
mice
vnt
respect
vero
cell
isol
set
merspp
neutral
assay
also
conveni
way
measur
nab
titer
base
lentiviru
core
report
luciferas
spike
protein
display
method
wide
use
mainli
assess
humor
immun
respons
laboratori
condit
instead
unavail
viru
laboratori
also
allow
test
rang
merspp
base
spike
protein
variou
develop
vaccin
human
use
long
process
may
take
decad
take
vaccin
bench
clinic
licensur
given
product
coher
collabor
clinician
scientist
regul
pharmaceut
industri
yet
one
big
obstacl
vaccin
compani
take
develop
licens
case
although
mortal
rate
alreadi
high
least
outbreak
seem
sporad
nosocomi
zoonot
may
pose
risk
seriou
global
major
infect
malaria
hiv
tb
influenza
exampl
influenza
outbreak
may
becom
global
epidem
matter
hour
mass
era
live
outbreak
occur
arabian
peninsula
first
isol
human
contact
consider
popul
dromedari
camel
less
number
camel
eastern
africa
infect
report
outsid
arabian
peninsula
china
europ
unit
state
caus
outbreak
presum
stricter
infect
control
measur
could
due
less
camel
contact
absenc
camel
popul
countri
far
document
outbreak
outsid
primari
region
korean
outbreak
start
index
patient
travel
back
arabian
gulf
state
outbreak
infect
peopl
mortal
rate
contain
month
like
strict
infect
control
therefor
pharmaceut
compani
may
discourag
develop
vaccin
infect
seem
sporad
nosocomi
zoonot
sustain
transmiss
ii
might
easili
contain
effect
infect
control
practic
iii
might
disappear
long
time
strict
public
health
measur
taken
similar
happen
industri
entiti
interest
hope
govern
least
endem
area
could
consid
fund
vaccin
develop
basic
earli
studi
clinic
trial
approv
market
although
affect
countri
rich
ksa
qatar
uae
might
look
quicker
measur
contain
viru
even
measur
expens
vaccin
take
long
labori
effort
exampl
tertiari
hospit
riyadh
ksa
one
biggest
middl
east
bed
visit
er
per
annum
vip
royal
clinic
hit
outbreak
august
result
case
mortal
hospit
respond
sever
action
regardless
cost
among
close
hospit
week
build
separ
er
flulik
symptom
sever
neg
pressur
room
construct
car
screen
checkpoint
entranc
medic
citi
direct
flulik
patient
new
er
without
contact
hospit
reopen
pay
overtim
staff
catch
clinic
schedul
respons
took
week
complet
help
clear
larg
hospit
astonishingli
short
time
person
commun
dr
bandar
al
knawi
ceo
king
abulaziz
medic
therefor
rich
govern
public
pressur
might
prefer
implement
similar
action
major
hospit
quick
effici
respons
might
favor
fund
lengthi
process
vaccin
develop
yet
saudi
ministri
health
shown
interest
vaccin
earli
stage
develop
held
special
workshop
riyadh
novemb
invit
offici
major
fund
bodi
vaccinologist
interest
vaccin
aim
help
acceler
process
discuss
scienc
fund
plan
set
blueprint
subject
also
explan
saudi
fda
regul
trial
attempt
welcom
vaccin
clinic
trial
ksa
question
vaccin
becom
critic
scientist
conduct
vaccin
studi
anim
model
approach
phase
human
clinic
trial
two
vaccin
begun
clinic
test
vaccin
codevelop
inovio
pharmaceut
geneon
life
scienc
inc
test
human
walter
reed
armi
institut
second
vaccin
schedul
phase
safeti
trial
vaccin
show
promis
protect
result
dromedari
phase
trial
focu
safeti
given
vaccin
test
healthi
volunt
therefor
anticip
safeti
record
mva
dna
vaccin
vaccin
could
move
phase
ii
immunogen
safeti
trial
bigger
number
subject
end
might
also
move
endem
area
provid
fund
avail
howev
target
popul
receiv
vaccin
would
import
question
epidemiolog
studi
infect
mainli
male
health
care
worker
peopl
comorbid
diabet
mellitu
heart
therefor
factor
would
set
criteria
select
particip
phase
ii
trial
follow
safeti
trial
efficaci
trial
could
consid
next
scientist
gener
use
curabl
strain
pathogen
challeng
vaccin
assess
respect
vaccin
efficaci
done
malaria
vaccin
trial
exampl
studi
see
hodgson
et
viral
infect
hiv
scientist
need
reli
natur
infect
challeng
model
therefor
vaccin
efficaci
vaccin
health
care
worker
especi
er
wait
next
outbreak
appear
assess
vaccin
efficaci
would
way
efficaci
trial
set
altern
vaccin
contact
infect
peopl
outbreak
would
way
assess
whether
contact
protect
compar
unvaccin
contact
infect
peopl
approach
call
ring
vaccin
use
smallpox
erad
campaign
vaccin
program
recent
use
ebola
vaccin
howev
may
becom
difficult
reason
first
requir
effici
coordin
scientist
clinician
health
offici
endem
area
identifi
volunt
get
consent
particip
vaccin
within
right
time
second
requir
quick
action
peak
infect
may
last
long
week
onset
mer
third
importantli
requir
identifi
larg
number
infect
peopl
high
number
contact
n
will
particip
howev
cluster
outbreak
usual
less
make
difficult
conduct
phase
iii
efficaci
trial
outbreak
date
none
test
vaccin
fail
induc
nab
protect
mice
partial
protect
larg
anim
tabl
viru
seem
polymorph
spike
protein
involv
tropism
cell
entri
contain
neutral
epitop
therefor
vaccin
could
becom
avail
year
suffici
financi
logist
support
increas
evid
camel
sourc
infect
use
concept
vaccin
camel
might
decreas
human
case
especi
mild
asymptomat
infect
may
undetect
import
circul
viru
figur
develop
vaccin
anim
would
requir
less
time
less
cost
fewer
regul
cgmp
manufactur
govern
affect
arabian
area
will
contain
viru
mass
camel
screen
program
identifi
vaccin
seroneg
camel
larg
number
camel
alreadi
seroposit
camel
vaccin
also
focu
immun
newborn
pregnant
camel
well
seroneg
import
camel
lastli
respons
futur
emerg
coronaviru
would
develop
univers
vaccin
incorpor
conserv
region
coronavirus
howev
might
difficult
coronavirus
share
similar
neutral
epitop
immunodomin
epitop
abl
induc
immun
therefor
realist
approach
would
increas
prepared
respond
rapidli
emerg
pathogen
necessarili
coronavirus
includ
develop
technolog
easili
use
vaccin
develop
exampl
cgmp
manufactur
mva
viral
vector
use
vaccin
base
chicken
embryo
fibroblast
primari
cell
ideal
larg
scale
manufactur
develop
cheaper
effici
cgmp
cell
line
instead
primari
cell
would
acceler
vaccin
anoth
exampl
would
develop
technolog
exclud
transfer
vaccin
would
reduc
cost
time
great
extent
make
world
prepar
distribut
vaccin
next
emerg
pathogen
